Acute myeloid leukemia (AML) is a relentless hematological malignancy characterized by overproduction of hematopoietic precursor cells with impaired differentiation. Increasing evidences suggest that the development of AML is a multistep process that requires collaboration of at least two classes of mutations: class I mutations activate signal-transduction pathway and confer a proliferation advantage to hematopoietic cells, and the class II mutations affect transcription factors and serve primarily to impair hematopoietic differentiation. 1, 2 The PTPN11 gene encodes human SHP2, a nonreceptor tyrosine phosphatase on chromosome 12q24, which participates in signal events downstream of the receptors of growth factors and cytokines and plays a key role in the proliferation and survival of hematopoietic cells. Germ line PTPN11 mutations in patients afflicted with Noonan syndrome were first reported by Tartaglia et al. 3 Subsequently, somatic PTPN11 mutations were also found in patients with juvenile myelomonocytic leukemia, myelodysplastic syndrome, childhood AML and acute lymphoblastic leukemia. To the best of our knowledge, however, the characteristics of adult AML with PTPN11 mutation have not been comprehensively studied yet, and the gene alteration that is cooperative with the PTPN11 mutation in the pathogenesis of AML remains largely unknown. In this study, we investigated prevalence and clinical relevance of PTPN11 mutations and their association with other genetic changes from 272 consecutive patients with primary AML. PTPN11 mutations were detected by PCR and direct sequencing using the primers covering exons 3 and 13. 4 Mutational analyses of N-RAS, K-RAS, NPM1, FLT3/ITD, FLT3/TKD, CEBPA, KIT, AML1 and MLL/PTD were performed as previously described. 5, 6 The correlation of genetic mutations with clinical and laboratory characteristics is summarized in Supplementary Table 1. Among the 272 AML patients recruited, 165 were males and 107 were females with a median age of 52.5 years (range, 19-90). Overall, 15 PTPN11 mutations were detected in 14 (5.1%) patients. These PTPN11 alterations were exclusively missense mutations (Table 1) affecting residues located within the N-SH2 (12 cases) and PTP domains (2 cases). The PTPN11 mutation disappeared at complete remission in the four patients who had paired bone marrow samples for analysis ( Figure 1 ). The mutation occurred more frequently in FAB M4 or M5 subtypes than in other subtypes (10.4 vs 3.4%, P ¼ 0.049). The AML patients with PTPN11 mutations were older than those Letters to the Editor without this mutation (median 64 vs 51 years, P ¼ 0.036) and had a trend of higher median white blood cell counts at diagnosis than those without (51.2 Â 10 9 vs 19.4 Â 10 9 per liter, P ¼ 0.069). Apart from this, there were no differences in other clinical parameters, including hemoglobin, platelet count and lactate dehydrogenase value between patients with and without mutations.
As best we are aware, there was a relative paucity of relevant cytogenetic data for AML patients with PTPN11 mutation in the literature, such that the relationship between the PTPN11 mutation and certain cytogenetic change remains unknown. In this study, the PTPN11 mutation was found to be closely associated with a normal karyotype. Among those patients who exhibited a normal karyotype, 8.0% featured a PTPN11 mutation, compared with 2.1% of those individuals who demonstrated chromosomal abnormalities (P ¼ 0.044). No PTPN11 mutation was seen for patients with t(15;17), t(8;21) or inv(16). For immunophenotyping, the PTPN11 mutation was closely associated with expression of CD14, but not with expression of other markers, on leukemia cells (P ¼ 0.026, data not shown).
This is the first report to correlate PTPN11 mutations with other gene alterations among adult AML patients. While the overall incidence of the FLT3/ITD was 24.7% for our patients, none of the 14 patients who demonstrated PTPN11 mutations revealed an FLT3/ITD (Table 2) . In other words, the PTPN11 and FLT3/ITD mutations were mutually exclusive (P ¼ 0.025). On the other hand, 6 (46.2%) of the 13 patients with PTPN11 mutations who had mutation analysis of NPM1 gene showed concurrent NPM1 mutations (Tables 1 and 2 ), including one (no. 791) with an extra NRAS mutation, compared with 51 (20.2%) of the patients without PTPN11 mutations did so (P ¼ 0.037). In other words, 6 (10.5%) of the 57 patients with NPM1 mutations showed PTPN11 mutations. None of the 14 patients who expressed PTPN11 mutations revealed any simultaneous alteration of KIT, CEBPA, KRAS or FLT3/TKD, although three of these patients revealed AML1 mutations and the other one had MLL/ PTD (Tables 1 and 2 ). These findings are compatible with a twohit theory of leukemogenesis and suggest that PTPN11 mutants (class I mutation) may cooperate with class II mutations or NPM1 mutations, but usually not with class I mutations in the multistep pathogenesis of AML.
An important question here is whether mutant PTPN11 significantly affects the treatment response or survival of AML patients. Tartaglia et al. revealed that the PTPN11 mutation constituted no prognostic significance for pediatric patients with AML. In this study, similar findings were found for adult AML patients. The complete remission rate (75 vs 62%), the overall survival (median 13±8.95 vs 25.5±6.54 months, Figure 2a ) and relapse-free survival (19 ± 3.27 vs 25 ± 14.04 months) were similar between patients with and without PTPN11 mutations. However, subgroup analysis did reveal that the PTPN11 mutation was a poor risk factor for overall survival of AML patients who did not have NPM1 mutations (P ¼ 0.001, Figure 2b ). It is possible that a cooperative gene alteration, such as the AML1 mutation or MLL/PTD, may influence the overall outcome for such patients. No such difference was apparent among patients without NPM1 mutations (P ¼ 0.738, Figure 2c) .
In short, we demonstrated that although PTPN11 mutations were not a frequent molecular event in adult patients with primary AML, those patients with this gene mutation did reveal some distinct clinical and biological characteristics. Typically, they were usually elderly persons and had higher incidence of M4/M5 subtype, CD14 expression, a normal karyotype and concurrent NPM1 mutation, but no alteration of the FLT3 in leukemia cells. It also implied that the PTPN11 mutation, in cooperation with the NPM1 mutation or a class II mutation, may play a role for leukemogenesis in a proportion of adult patients afflicted with AML. Further comprehensive studies are needed to disclose the molecular mechanisms of the interactions between Overall survival according to PTPN11 status. (a) There was no survival difference in overall survival between adult acute myeloid leukemia (AML) patients with and those without PTPN11 mutations (P ¼ 0.284, as revealed by the logrank test). (b) Among the patients not featuring the NPM1 mutation, patients that did express PTPN11 mutations revealed a significantly shorter overall survival than those without PTPN11 mutations. (P ¼ 0.001 by the logrank test). (c) No survival difference was observed between patients with and without PTPN11 mutations among AML patients with the NPM1 mutation. (P ¼ 0.738 by the log rank test).
PTPN11 mutants and other genetic alterations as regards the pathogenesis of AML.
